The portfolio will be transferred to Lupin on Dec. 31, subject to regulatory approvals and certain closing conditions, the companies said in a statement on Tuesday.
The acquisition, which will be done by Lupin's Japanese generic drug unit Kyowa Pharmaceutical Industry Co Ltd, will give Lupin access to Japanese branded pharmaceutical market and strengthen its speciality business portfolio, they said.
The 21 products currently have sales of $90 million and cover therapy areas such as central nervous system, oncology, cardiovascular and anti-infectives, the statement said.
($1 = 102.6100 yen)
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.